A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer
The primary aim is to evaluate the safety (Phase I components) of administering bexarotene (Targretin®, LGD1069) oral capsules in combination with two Taxol® and carboplatin (Paraplatin®) schedules to patients with stage IIIB and IV non-small cell lung cancer. This study will also evaluate the preliminary efficacy (Phase II component) of bexarotene oral capsules in combination with the weekly Taxol® schedule and carboplatin in these patients.
Checked against the public recordLast updated Mar 6, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Interventions being studied
- Drug: Bexarotene (targretin); Drug: Bexarotene (targretin)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * unresectable stage IIIB or IV NSCLC * adequate bone marrow, hepatic, thyroid and renal function Exclusion Criteria: * peripheral neuropathy \>= grade 2 * gastrointestinal abnormalities * known hypersensitivity to retinoids
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Norris Cotton Cancer CenterLebanon, New Hampshire
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 6, 2019. Always confirm current availability with the study team.